Industry News
Biotechnology Industry News
A new Caribbean company has…
A new Caribbean company has emerged to enter the increasingly crowded T-cell engager space. Excalipoint, incorporated in the Cayman Islands, is paying $10 million upfront to China’s Lepu Biopharma in return for the rights to
A phase 3 trial of Spine…
A phase 3 trial of Spine BioPharma’s chronic low back pain candidate has missed its primary endpoint. But, with the biotech pinning the failure on a “very high sham control response,” management plans to meet
Sanofi is handing over $130…
Sanofi is handing over $130 million upfront for the China rights to Arrowhead Pharmaceuticals’ rare metabolic disease treatment that is currently being considered for approval by Chinese regulators.
4D Molecular Therapeutics has…
4D Molecular Therapeutics has posted 60-week data on a gene therapy, providing evidence of durability in diabetic macular edema and sending its stock up more than 40% in premarket trading.
Allogene Therapeutics has reported…
Allogene Therapeutics has reported a patient death tied to its anti-CD52 monoclonal antibody used for lymphodepletion in its key CAR-T cell therapy trial for large B-cell lymphoma (LBCL).
After the surprise departure of…
After the surprise departure of longtime CEO Lars Fruergaard Jørgensen in May, Danish pharma giant Novo Nordisk didn’t take too long to find a successor. Maziar Mike Doustdar, currently the company’s EVP of international operations,
A PD-L1xVEGF bispecific antibody…
A PD-L1xVEGF bispecific antibody from China’s ImmuneOnco Biopharmaceuticals has shown early promise in shrinking lung tumors, instilling hope that the asset can succeed in a newly approved U.S. trial.
AbbVie is ending development of an…
AbbVie is ending development of an IL-1 asset as a monotherapy in ulcerative colitis after a phase 2 study failed to demonstrate sufficient efficacy results.
Nuvectis Pharma has dropped plans…
Nuvectis Pharma has dropped plans to develop NXP800 in ovarian cancer after tallying two unconfirmed partial responses in a phase 1b study.
Frazier Life Sciences has gathered…
Frazier Life Sciences has gathered an impressive $1.3 billion in capital commitments for its 12th venture fund aimed at private early-stage biotechs.
AbbVie has reportedly added…
AbbVie has reportedly added Gilgamesh Pharmaceuticals to its shopping list. The Big Pharma teamed up with Gilgamesh last year and, according to Bloomberg, is now in talks about buying the mental health biotech outright for
The FDA has missed the date for…
The FDA has missed the date for Coya Therapeutics’ investigational new drug application, citing a lack of resources and its current workload as reasons for the delay, according to a legal filing from the biotech.
Weeks after the biotech gave up on…
Weeks after the biotech gave up on a psoriasis trial of one drug that was hit with a partial clinical hold, Vyne's lead candidate has now failed a midstage vitiligo trial.
Cardiff Oncology has reported…
Cardiff Oncology has reported updated results from its phase 2 colorectal cancer trial, laying out data it believes can support talks with the FDA about a registrational program. Investors responded by sending the biotech’s share
Madrigal Pharmaceuticals is paying…
Madrigal Pharmaceuticals is paying $120 million upfront for a preclinical GLP-1 receptor agonist that the biopharma plans to pair up with its recently approved fatty liver disease med Rezdiffra.
GSK’s cobolimab has become the…
GSK’s cobolimab has become the latest anti-TIM-3 antibody to flunk a crucial oncology test, as the pharma absorbs a more than $600 million hit from its anti-TIGIT drug failure.
Kissei Pharmaceutical is paying…
Kissei Pharmaceutical is paying Viridian Therapeutics $70 million upfront for Japanese rights to a pair of thyroid eye disease drug candidates, establishing the drugmaker as a potential rival to Amgen.
As Merck & Co. rolls out a…
As Merck & Co. rolls out a widespread cost-cutting initiative, the pharma is dropping an autoimmune asset acquired a few years ago in a nearly $2 billion biotech takeover.
Quoin Pharmaceuticals has ended…
Quoin Pharmaceuticals has ended development of two programs, pulling back from the assets as it starts to gear up for the anticipated approval of its lead candidate.
Bausch Health has struck a deal to…
Bausch Health has struck a deal to buy Durect for $63 million upfront, landing a phase 3-ready liver disease candidate that the companies believe has blockbuster potential.